Extremely large outlier treatment effects may be a footprint of bias in trials from less developed countries: randomized trials of gabapentinoids.

[1]  A. Sutton,et al.  Baseline Morphine Consumption May Explain Between-Study Heterogeneity in Meta-analyses of Adjuvant Analgesics and Improve Precision and Accuracy of Effect Estimates , 2017, Anesthesia and analgesia.

[2]  P. L. Petersen,et al.  Gabapentin in procedure-specific postoperative pain management – preplanned subgroup analyses from a systematic review with meta-analyses and trial sequential analyses , 2017, BMC Anesthesiology.

[3]  J. Ioannidis,et al.  Very large treatment effects in randomised trials as an empirical marker to indicate whether subsequent trials are necessary: meta-epidemiological assessment , 2016, British Medical Journal.

[4]  P. L. Petersen,et al.  Gabapentin for post‐operative pain management – a systematic review with meta‐analyses and trial sequential analyses , 2016, Acta anaesthesiologica Scandinavica.

[5]  John P. A. Ioannidis,et al.  Reproducible Research Practices and Transparency across the Biomedical Literature , 2016, PLoS biology.

[6]  J. Lund,et al.  A systematic review and meta‐regression analysis of prophylactic gabapentin for postoperative pain , 2015, Anaesthesia.

[7]  J. Ioannidis,et al.  Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials , 2014, BMJ : British Medical Journal.

[8]  J. Ioannidis.  Clarifications on the application and interpretation of the test for excess significance and its extensions , 2013 .

[9]  Emergence of large treatment effects from small trials--reply. , 2013, JAMA.

[10]  J. Ioannidis,et al.  Comparative effect sizes in randomised trials from less developed and more developed countries: meta-epidemiological assessment , 2013, BMJ : British Medical Journal.

[11]  S. Vedula,et al.  Differences in Reporting of Analyses in Internal Company Documents Versus Published Trial Reports: Comparisons in Industry-Sponsored Trials in Off-Label Uses of Gabapentin , 2013, PLoS medicine.

[12]  John P A Ioannidis,et al.  Empirical evaluation of very large treatment effects of medical interventions. , 2012, JAMA.

[13]  S. Vedula,et al.  Implementation of a publication strategy in the context of reporting biases. A case study based on new documents from Neurontin® litigation , 2012, Trials.

[14]  J. Ross,et al.  Study of neurontin: titrate to effect, profile of safety (STEPS) trial: a narrative account of a gabapentin seeding trial. , 2011, Archives of internal medicine.

[15]  Raymond Miller,et al.  A Comparison of the Pharmacokinetics and Pharmacodynamics of Pregabalin and Gabapentin , 2010, Clinical pharmacokinetics.

[16]  Kay Dickersin,et al.  Outcome reporting in industry-sponsored trials of gabapentin for off-label use. , 2009, The New England journal of medicine.

[17]  Dimitrios G Goulis,et al.  Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis. , 2009, Clinical therapeutics.

[18]  J. Ioannidis,et al.  An exploratory test for an excess of significant findings , 2007, Clinical trials.

[19]  M. Chren,et al.  Narrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry Documents , 2006, Annals of Internal Medicine.

[20]  Miroslav Backonja,et al.  Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. , 2003, Clinical therapeutics.

[21]  L S Rothenberg,et al.  Conflict of interest policies in science and medical journals: Editorial practices and author disclosures , 2001, Science and engineering ethics.

[22]  S. Chinn.  A simple method for converting an odds ratio to effect size for use in meta-analysis. , 2000, Statistics in medicine.

[23]  Z A Kadir,et al.  Gabapentin for drug-resistant partial epilepsy. , 2000, The Cochrane database of systematic reviews.

[24]  D. Chadwick,et al.  A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures , 1998, Neurology.

[25]  S. Krimsky,et al.  Financial interest and its disclosure in scientific publications. , 1998, JAMA.